AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enroll...AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enrolled to investigate the expression of mi R-20 a and let-7a using quantitative real-time PCR. The expression of mi R-20 a and let-7a was compared between ESCC patients and healthy subjects. The plasma levels of mi R-20 a and let-7a in relation to patient clinicopathologic parameters, the receiver operating characteristic(ROC) curve, and the sensitivity and specificity of mi R-20 a and let-7a in ESCC diagnosis were analyzed.RESULTS: Plasma levels of mi R-20 a were significantly higher in ESCC patients than in healthy controls, and plasma levels of let-7 were lower in ESCC patients than in healthy controls(both P < 0.05). The area under the ROC curve of mi R-20 a was 0.767(95%CI: 0.677-0.857; P < 0.001), when the cut-off value was set at 4.77, the sensitivity and specificity were 64.3% and 75.0%, respectively. The area under the ROC curve of let-7a was 0.829(95%CI: 0.754-0.904; P < 0.001), when the cut-off value was set at 6.22, the sensitivity and specificity were 74.3% and 85.0%, respectively. Thus, the sensitivity and specificity of let-7a were higher than those of mi R-20 a. The median relative plasma expression of let-7a in clinical stage Ⅲ/Ⅳ(0.24) was lower than that in stage Ⅰ/Ⅱ(0.42), while the expression of mi R-20 a according to stage was not statistically different. The expressions of mi R-20 a and let-7a were not related to gender, age, tumor diameter, tumor grade, or pathologic stage.CONCLUSION: Plasma mi R-20 a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.展开更多
This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor mi...This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor microenvironments(TME)by inhibiting M2-tumor-associated macrophage(M2-TAM)polarization via Wnt/β-catenin pathway modulation.Recent research highlights the crucial role of TAMs and their polarization towards the M2 phenotype in promoting HCC progression.Epigenetic regulation,particularly through microRNAs(miR),has emerged as a key factor in modulating immune responses and TAM polarization in the TME,influencing treatment responses and tumor progression.This editorial focuses on miR-206,which has been found to inhibit HCC cell proliferation and migration and promote apoptosis.Moreover,miR-206 enhances anti-tumor immune responses by promoting M1-polarization of Kupffer cells,facilitating CD8+T cell recruitment and suppressing liver cancer stem cell expansion.However,challenges remain in understanding the precise mechanisms regulating miR-206 and its potential as a therapeutic agent.Targeting epigenetic mechanisms and improving strategies,whether through pharmacological or genetic approaches,offer promising avenues to sensitize tumor cells to chemotherapy.Understanding the intricate interactions between cancer and non-coding RNA regulation opens new avenues for developing targeted therapies,potentially improving HCC prognosis.展开更多
基金Supported by Medical Scientific Research Foundation of Health Department of Henan Province of China,No.201403077
文摘AIM: To investigate the expressions of micro RNA-20a(mi R-20a) and let-7a in esophageal squamous cell carcinoma(ESCC) and their diagnostic value. METHODS: Seventy patients with ESCC and 40 healthy subjects were enrolled to investigate the expression of mi R-20 a and let-7a using quantitative real-time PCR. The expression of mi R-20 a and let-7a was compared between ESCC patients and healthy subjects. The plasma levels of mi R-20 a and let-7a in relation to patient clinicopathologic parameters, the receiver operating characteristic(ROC) curve, and the sensitivity and specificity of mi R-20 a and let-7a in ESCC diagnosis were analyzed.RESULTS: Plasma levels of mi R-20 a were significantly higher in ESCC patients than in healthy controls, and plasma levels of let-7 were lower in ESCC patients than in healthy controls(both P < 0.05). The area under the ROC curve of mi R-20 a was 0.767(95%CI: 0.677-0.857; P < 0.001), when the cut-off value was set at 4.77, the sensitivity and specificity were 64.3% and 75.0%, respectively. The area under the ROC curve of let-7a was 0.829(95%CI: 0.754-0.904; P < 0.001), when the cut-off value was set at 6.22, the sensitivity and specificity were 74.3% and 85.0%, respectively. Thus, the sensitivity and specificity of let-7a were higher than those of mi R-20 a. The median relative plasma expression of let-7a in clinical stage Ⅲ/Ⅳ(0.24) was lower than that in stage Ⅰ/Ⅱ(0.42), while the expression of mi R-20 a according to stage was not statistically different. The expressions of mi R-20 a and let-7a were not related to gender, age, tumor diameter, tumor grade, or pathologic stage.CONCLUSION: Plasma mi R-20 a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
文摘This letter comments on the recently published manuscript by Huang et al in the World Journal of Gastroenterology,which focused on the immunomodulatory effect of Calculus bovis on hepatocellular carcinoma(HCC)tumor microenvironments(TME)by inhibiting M2-tumor-associated macrophage(M2-TAM)polarization via Wnt/β-catenin pathway modulation.Recent research highlights the crucial role of TAMs and their polarization towards the M2 phenotype in promoting HCC progression.Epigenetic regulation,particularly through microRNAs(miR),has emerged as a key factor in modulating immune responses and TAM polarization in the TME,influencing treatment responses and tumor progression.This editorial focuses on miR-206,which has been found to inhibit HCC cell proliferation and migration and promote apoptosis.Moreover,miR-206 enhances anti-tumor immune responses by promoting M1-polarization of Kupffer cells,facilitating CD8+T cell recruitment and suppressing liver cancer stem cell expansion.However,challenges remain in understanding the precise mechanisms regulating miR-206 and its potential as a therapeutic agent.Targeting epigenetic mechanisms and improving strategies,whether through pharmacological or genetic approaches,offer promising avenues to sensitize tumor cells to chemotherapy.Understanding the intricate interactions between cancer and non-coding RNA regulation opens new avenues for developing targeted therapies,potentially improving HCC prognosis.
